2/3
03:06 pm
rgnx
RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm
Low
Report
RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm
2/3
01:57 pm
rgnx
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
1/29
07:01 pm
rgnx
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
1/29
06:06 pm
rgnx
Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action
Medium
Report
Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action
1/29
10:05 am
rgnx
REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/29
08:03 am
rgnx
REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
Medium
Report
REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
1/28
02:16 pm
rgnx
INVESTOR ALERT: Investigation of REGENXBIO Inc. (RGNX) by Holzer & Holzer, LLC
Low
Report
INVESTOR ALERT: Investigation of REGENXBIO Inc. (RGNX) by Holzer & Holzer, LLC
1/28
11:23 am
rgnx
Regenxbio gene therapy trials suspended by FDA over safety worries [Yahoo! Finance]
Low
Report
Regenxbio gene therapy trials suspended by FDA over safety worries [Yahoo! Finance]
1/28
07:30 am
rgnx
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
High
Report
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
1/27
07:02 pm
rgnx
REGENXBIO (NASDAQ:RGNX) was given a new $37.00 price target on by analysts at Barclays PLC.
High
Report
REGENXBIO (NASDAQ:RGNX) was given a new $37.00 price target on by analysts at Barclays PLC.
1/27
08:31 am
rgnx
REGENXBIO: Key FDA Decision On Hunter Syndrome Just Weeks Away [Seeking Alpha]
Medium
Report
REGENXBIO: Key FDA Decision On Hunter Syndrome Just Weeks Away [Seeking Alpha]
1/19
05:31 pm
rgnx
REGENXBIO Inc. (RGNX): A Bull Case Theory [Yahoo! Finance]
Low
Report
REGENXBIO Inc. (RGNX): A Bull Case Theory [Yahoo! Finance]
1/11
03:47 pm
rgnx
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program [Yahoo! Finance]
Low
Report
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program [Yahoo! Finance]
1/11
03:00 pm
rgnx
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
Low
Report
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
12/19
10:04 am
rgnx
REGENXBIO (NASDAQ:RGNX) was given a new $45.00 price target on by analysts at Stifel Nicolaus.
Low
Report
REGENXBIO (NASDAQ:RGNX) was given a new $45.00 price target on by analysts at Stifel Nicolaus.
12/18
07:45 am
rgnx
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/18
07:05 am
rgnx
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/15
08:44 am
rgnx
REGENXBIO (NASDAQ:RGNX) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Medium
Report
REGENXBIO (NASDAQ:RGNX) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
11/27
07:01 pm
rgnx
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/26
05:35 pm
rgnx
Regenxbio files $300M mixed shelf offering [Seeking Alpha]
Low
Report
Regenxbio files $300M mixed shelf offering [Seeking Alpha]
11/25
07:50 am
rgnx
REGENXBIO to Participate in Upcoming Investor Conference [Yahoo! Finance]
Low
Report
REGENXBIO to Participate in Upcoming Investor Conference [Yahoo! Finance]
11/25
07:05 am
rgnx
REGENXBIO to Participate in Upcoming Investor Conference
Medium
Report
REGENXBIO to Participate in Upcoming Investor Conference
11/24
02:05 am
rgnx
Medium
Report
11/20
08:07 am
rgnx
REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
Low
Report
REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.